Imstar Therapeutics Secures Funding to Advance IMS-088 for ALS

British Columbia-based biotechnology company ImStar Therapeutics has secured seed financing to advance preclinical testing of its lead candidate, IMS-088, for ALS (see Dec 2013 news). IMS-088 is a therapeutic compound derived from withaferin A, which improves function in TDP-43 and SOD1 mouse models of ALS (see Dec 2011 news, Patel et al., 2015). The drug targets TDP-43-related NF-kB activation, and exerts immunosuppressive effects. Investors in the new round of financing are Accel-Rx, BDC Capital, and AviTx, a company co-founded by Prize4Life founder Avichai Kremer.

Click here to read more.

disease-als topic-preclinical topic-randd
Share this: